



## ANNEX A → 510(K) SUMMARY

Page 1/1

**Trade name:** Audio Prosthesis- Audio Technologies  
**Common name:** Prothesis for otosurgery  
**Classification name:** Partial Ossicular Replacement Prosthesis  
 Total Ossicular Replacement Prosthesis

MAR 23 2009

**submitter:** AUDIO TECHNOLOGIES S.r.l.  
 Via Valleria 42  
 I-29100 – PIACENZA - Italy

**Official contact:** dr. Franco Beoni (General Director)  
 telephone: +39.0523.778864  
 fax number: +39.0523.770019  
 e-mail: info@audiotechnologies.it

**Date prepared:** November 25<sup>th</sup>, 2008

**predicate devices:**

The *Audio Prosthesis - Audio Technologies*, are substantially equivalent to *Richards - marketed by Smith & Nephew*, and/or *Xomed - marketed by Xomed*, and/or *Exmoor - marketed by Exmoor Plastics* and also *Audio Technologies prosthesis*.

**Description:**

Otosurgical prosthesis of the middle ear, implanted, in a permanent manner, in patients affected with pathologies of the middle ear.

Otosurgical prosthesis of the middle hear, are manufactured from a wide variety of materials: platinum (Pt), titanium, polyethylene (PE), stainless steel, hydroxylapatite (HA), polytetrafluoroethylene (PTFE), gold, polimetilxilossano (silicon) and Nitinol, or combination of these materials.

Numerous designs are available for replacement of any or all of the bones of the ossicular chain.

**Intended use:**

For replacement for any or all of the bones of the ossicular chain in the middle ear

**Indications for use**

Audio prostheses are successfully employed in case of otosclerosis, stapedo-vestibular ankylosis, outcome of otitis media, trauma, middle ear congenital malformations. Possible complication due to the use of prostheses in the middle ear include: fixation, displacement, extrusion of the prosthesis, incus necrosis, tympanic membrane perforation, perilymph fistula, labyrinthitis, otitis media, occlusion of oval and round window.

Some of the prostheses are manufactured in different lengths, some others shall be trimmed during the surgical operation. Nevertheless the length of all the prostheses should be carefully assessed by means of a microsurgical gauge (code 02.14)

**Comparison to predicate devices:**

These devices have the same indications for use (Partial / Total Ossicular Replacement Prosthesis, for reconstruction of the ossicular chain that has lost its function, due to disease, trauma, or congenital defect), the same technological characteristics, i.e. materials (all widely accepted for middle ear reconstruction), and the same general design.

Slight design differences between Audio Technologies Prosthesis and the predicate devices should not affect the safety and effectiveness

**Audio Technologies Srl**

Sede legale: via Valleria, 42 - 29100 Piacenza (Italy) - tel. +39 0523 778864, fax +39 0523 770019  
 Produzione: via dell'Artigianato, 8 - 29020 Gossolengo, Piacenza (Italy)  
 Cod. Fisc./Part. IVA 01086720339 - Reg. Imprese 01086720339 - R.E.A. 126383 - Cap. Soc. i.v. € 24000,00 -  
 info@audiotechnologies.it - www.audiotechnologies.it



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Audio Technologies S.R.L.  
c/o Franco Beoni  
Via Vallera, 42  
Piacenza, Italy 1-29100

**MAR 23 2009**

Re: K083780  
Trade/Device Name: Total/Partial Ossicular Replacement Prosthesis  
Regulation Number: 21 CFR 874.3495  
Regulation Name: Total Ossicular Replacement Prosthesis  
Regulatory Class: Class II  
Product Code: ETA, ETB  
Dated: March 3, 2009  
Received: March 11, 2009

Dear Dr. Beoni :

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Malvina B. Eydelman, M.D.

Director

Division of Ophthalmic and Ear, Nose  
and Throat Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

**Section 4. Indications for use statement**

**Indication for Use**

510(k) Number (if known): K083780  
Device Name: Prosthesis for otosurgery  
Indication For Use:

Otosurgical prosthesis of the middle ear, implanted, in a permanent manner, in patients affected with pathologies of the middle ear.

Audio prostheses are successfully employed in case of otosclerosis, stapedo-vestibular ankylosis, outcome of otitis media, trauma, middle ear congenital malformations. Possible complication due to the use of prostheses in the middle ear include: fixation, displacement, extrusion of the prosthesis, incus necrosis, tympanic membrane perforation, perilymph fistula, labyrinthitis, otitis media, occlusion of oval and round window.

Some of the prostheses are manufactured in different lengths, some others shall be trimmed during the surgical operation. Nevertheless the length of all the prostheses should be carefully assessed by means of a microsurgical gauge (code 02.14)

The implant must be carried out by a qualified surgeon.


Prescription Use YES  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use NO  
(Part 21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
**(Division Sign-Off)**  
**Division of Ophthalmic and Ear,**  
**Nose and Throat Devices**

510(k) Number K083780